
Gilead Monopoly Prevails Over Non-Discriminatory Access As Debated Hepatitis C Deal Sets Off
Gilead on 15 September struck voluntary licence deals with seven India-based generic manufacturers to expand access to its hepatitis C innovative drugs in developing countries. With a limited territory covered, this, yet deserving, pact raises doubts about the coherence of Indian counterparts at a time when there are no relevant patents in India, several pre-grant oppositions have been filed and unrestrained competition by compulsory licences could have been pursued, writes Daniele Dionisio.










